{"type":"trials","record":{"id":41625,"source_id":"clinicaltrials-gov","external_id":"NCT07389577","title":"A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)","brief_summary":"This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy and safety of JL14002 compared to Lucentis® in subjects with wAMD.","overall_status":"Completed","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","enrollment":443,"countries":["China"],"start_date":"2022-03-01","completion_date":"2024-09-23","last_update_date":"2026-02-05","source_url":"https://clinicaltrials.gov/study/NCT07389577","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 80 Years","comparator":"Active Comparator Arm 1 (Drug: Ranibizumab→JL14002 monoclonal antibody); Active Comparator Arm 2 (Drug:Ranibizumab)","organization":"Jecho Biopharmaceuticals Co., Ltd.","interventions":["JL14002 monoclonal antibody(Fixed dosing regimen)","Ranibizumab(Fixed dosing regimen)","JL14002 monoclonal antibody(PRN)","Ranibizumab(PRN)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Best-Corrected Visual Acuity (BCVA) Change From Baseline (No. of Letters) to Week 12 — Baseline (Day 0), Week 12","Proportion of subjects who gained at least 5,10 and 15 letters and lose 15 letters baseline to week 12,week 24 and week…","Change From Baseline in CRT(central retina thickness) by visit — Baseline (Day 0), Week 12, Week 24, Week 52","Change from baseline in CNV area from baseline to week 12 and week 52 — Baseline (Day 0), Week 12, Week 52","BCVA Change From Baseline by visit — Baseline (Day 0), Week 24, Week 52","Incidence of drug-related ocular and systemic adverse reactions at Week 12, Week 24, and Week 52. — Baseline (Day 0), W…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Wet Age-related Macular Degeneration","JL14002 monoclonal antibody(Fixed dosing regimen)","Ranibizumab(Fixed dosing regimen)","JL14002 monoclonal antibody(PRN)","Ranibizumab(PRN)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07389577","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-03-01 to 2024-09-23","comparator":"Active Comparator Arm 1 (Drug: Ranibizumab→JL14002 monoclonal antibody); Active Comparator Arm 2 (Drug:Ranibizumab)","confidence":"structured-source","population":"ALL · 50 Years to 80 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.843Z","intervention":["JL14002 monoclonal antibody(Fixed dosing regimen)","Ranibizumab(Fixed dosing regimen)","JL14002 monoclonal antibody(PRN)","Ranibizumab(PRN)"],"participants":443,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Best-Corrected Visual Acuity (BCVA) Change From Baseline (No. of Letters) to Week 12 — Baseline (Day 0), Week 12","Proportion of subjects who gained at least 5,10 and 15 letters and lose 15 letters baseline to week 12,week 24 and week…","Change From Baseline in CRT(central retina thickness) by visit — Baseline (Day 0), Week 12, Week 24, Week 52","Change from baseline in CNV area from baseline to week 12 and week 52 — Baseline (Day 0), Week 12, Week 52","BCVA Change From Baseline by visit — Baseline (Day 0), Week 24, Week 52","Incidence of drug-related ocular and systemic adverse reactions at Week 12, Week 24, and Week 52. — Baseline (Day 0), W…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41625","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}